

Drug Discovery Toxicology Specialty Section

ANNUAL REPORT: 2023–2024

May 1, 2023 to April 30, 2024

I. Officers:

<u>2023–2024</u>	<u>2024–2025</u>
President: Jonathan Maher Vice President: Satoko Kiyota Vice President-Elect: Wenyue Hu Secretary-Treasurer: Marianna Stamou Past President, Councilor: Brandon Jeffy Councilor: Laura Armstrong Councilor: Lauren Lewis Postdoctoral Representative: Dakota Robarts Graduate Student Representative: Zakiyah Henry	President: Satoko Kiyota Vice President: Wenyue Hu Vice President-Elect: Marianna Stamou Secretary-Treasurer: Sarah Carratt Past President, Councilor: Jonathan Maher Councilor: Laura Armstrong Councilor: Brita Kilburg-Basnyat Postdoctoral Representative: Dakota Robarts Graduate Student Representative: Zakiyah Henry

II. 2024 Membership total: 271

III. Key Outcomes and Accomplishments in 2023–2024:

The Drug Discovery Toxicology Specialty Section accomplished the following activities throughout the year.

- In-person meeting/mixer
- Mentoring/career development events
- Trainee awards conferred
- Paper of the year award
- Newsletter(s)
- Webinars
- Business meeting (communicated operations/finances to members)

IV. Collaborative Partnerships with Other SOT Organizations:

The Drug Discovery Toxicology Specialty Section collaborated with the following organizations within SOT.

- Computational Toxicology

V. Communication Methods:

The Drug Discovery Toxicology Specialty Section stayed in contact with its members throughout the year through the following mechanisms.

- ToXchange
- Emails through SOT Headquarters
- Specialty Section website
- Newsletter(s)

- Through Graduate Student/Postdoc Representatives
- LinkedIn

VI. Promotion of Inclusivity

The Drug Discovery Toxicology Specialty Section maintained an inclusive organization through the following activities.

- Nominate a diverse slate of candidates for elections
- Solicit equitable input from all executive committee leaders
- Utilize virtual meetings for convening Specialty Section leadership
- Utilize standardized rubrics for judging awards/posters
- Highlight trainee research
- Use multiple approaches to communicate with membership

VII. Mentoring and Career Development Activities:

The Drug Discovery Toxicology Specialty Section hosted the following mentoring activities throughout the year for its membership.

- Mentoring luncheon for students and postdocs at the annual meeting

VIII. Awards Given:

Trainee	6
Early Career	6
Mid Career	0
Late Career	0

IX. Key Outcomes and Improvements:

DDTSS was the primary endorser for a CE course and symposium session and an additional endorser for four sessions at the 2024 SOT Annual Meeting. DDTSS hosted a reception at the 2024 SOT Annual Meeting in Salt Lake City. There was a brief business meeting which included a report of section activities in the past year, award announcements, introductions of the 2023-2024 officers, and ample networking opportunities to connect with colleagues.

X. Strategic Plan:

The Drug Discovery Toxicology Specialty Section supported the following SOT Strategic Priorities.

- Proactively pursue impactful scientific content
- Support the development and application of tools that advance toxicology
- Effectively communicate scientific advances
- Foster connectivity across scientific disciplines
- Develop a talent pool of toxicologists for the future
- Provide training and education that reflects the needs of members
- Provide mentoring and networking opportunities for all career levels
- Enhance member recognition and visibility at all levels

XI. Scientific Topics of Interest:

The Drug Discovery Toxicology Specialty Section is interested in seeing the following topic areas developed into sessions at future SOT Annual Meetings.

- Safety assessments of novel technology in drug development; How we can compile available information (safety, biology, competitor's info, etc) into a meaningful visualization to increase efficiency for toxicologist to understand safety concerns and form

XII. Feedback to the Society:

- A. What is the one thing the Society should be doing that it currently does not do (or does not do effectively) that would be of importance/benefit to the members of the Specialty Section?

No feedback at this time.

- B. What is the one thing the Society is currently doing that impacts the Specialty Section that should be changed (e.g., stopped, modified, etc.)?

No feedback at this time.